BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20160475)

  • 1. Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
    Beierle EA; Ma X; Stewart J; Nyberg C; Trujillo A; Cance WG; Golubovskaya VM
    Cell Cycle; 2010 Mar; 9(5):1005-15. PubMed ID: 20160475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
    Heffler M; Golubovskaya VM; Dunn KM; Cance W
    Cancer Biol Ther; 2013 Aug; 14(8):761-72. PubMed ID: 23792569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the MYCN effector, FAK, in neuroblastoma.
    Davidoff AM
    Cell Cycle; 2010 Mar; 9(6):1026. PubMed ID: 20410685
    [No Abstract]   [Full Text] [Related]  

  • 4. MYCN, neuroblastoma and focal adhesion kinase (FAK).
    Beierle EA
    Front Biosci (Elite Ed); 2011 Jan; 3(2):421-33. PubMed ID: 21196322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
    Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
    Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
    Beierle EA; Ma X; Trujillo A; Kurenova EV; Cance WG; Golubovskaya VM
    Mol Carcinog; 2010 Mar; 49(3):224-34. PubMed ID: 19885861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
    Megison ML; Stewart JE; Nabers HC; Gillory LA; Beierle EA
    Clin Exp Metastasis; 2013 Jun; 30(5):555-68. PubMed ID: 23208732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
    Zhang H; Shao H; Golubovskaya VM; Chen H; Cance W; Adjei AA; Dy GK
    Br J Cancer; 2016 Jul; 115(2):203-11. PubMed ID: 27336608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interaction between FAK, MYCN, p53 and Mdm2 in neuroblastoma.
    Waters AM; Beierle EA
    Anticancer Agents Med Chem; 2014 Jan; 14(1):46-51. PubMed ID: 24041229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
    Golubovskaya VM; Huang G; Ho B; Yemma M; Morrison CD; Lee J; Eliceiri BP; Cance WG
    Mol Cancer Ther; 2013 Feb; 12(2):162-72. PubMed ID: 23243059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
    Steinestel K; Trautmann M; Jansen EP; Dirksen U; Rehkämper J; Mikesch JH; Gerke JS; Orth MF; Sannino G; Arteaga MF; Rossig C; Wardelmann E; Grünewald TGP; Hartmann W
    Mol Oncol; 2020 Feb; 14(2):248-260. PubMed ID: 31811703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FAK is a critical regulator of neuroblastoma liver metastasis.
    Lee S; Qiao J; Paul P; O'Connor KL; Evers MB; Chung DH
    Oncotarget; 2012 Dec; 3(12):1576-87. PubMed ID: 23211542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
    Zhang J; He DH; Zajac-Kaye M; Hochwald SN
    Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting focal adhesion kinase in neuroblastoma.
    Gillory L; Beierle EA
    Anticancer Agents Med Chem; 2010 Dec; 10(10):714-21. PubMed ID: 21269252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sunitinib suppress neuroblastoma growth through degradation of MYCN and inhibition of angiogenesis.
    Calero R; Morchon E; Johnsen JI; Serrano R
    PLoS One; 2014; 9(4):e95628. PubMed ID: 24759734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A small molecule focal adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-azoniatricyclo [3.3.1.1(3,7)]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
    Golubovskaya VM; Figel S; Ho BT; Johnson CP; Yemma M; Huang G; Zheng M; Nyberg C; Magis A; Ostrov DA; Gelman IH; Cance WG
    Carcinogenesis; 2012 May; 33(5):1004-13. PubMed ID: 22402131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
    Stafman LL; Williams AP; Marayati R; Aye JM; Markert HR; Garner EF; Quinn CH; Lallani SB; Stewart JE; Yoon KJ; Whelan K; Beierle EA
    Sci Rep; 2019 Sep; 9(1):13259. PubMed ID: 31519958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-MYC regulates focal adhesion kinase expression in human neuroblastoma.
    Beierle EA; Trujillo A; Nagaram A; Kurenova EV; Finch R; Ma X; Vella J; Cance WG; Golubovskaya VM
    J Biol Chem; 2007 Apr; 282(17):12503-16. PubMed ID: 17327229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.